SCL Science

SCL Science ROE

The Return on Equity (ROE) of SCL Science (246960.KQ) as of Oct 17, 2026 is -16.09 %. In the previous year, Return on Equity (ROE) was -24.04 % — a change of -33.06% (higher).

ROE

-16.09 %

YoY

-33.06%

Last updated:

In 2025, SCL Science's return on equity (ROE) was -16.09 %, a -33.06% increase from the -24.04 % ROE in the previous year.

The SCL Science ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-27.05 KRW
Jan 1, 2019
-26.45 KRW
Jan 1, 2020
-23.55 KRW
Jan 1, 2021
-49.90 KRW
Jan 1, 2022
-45.78 KRW
Jan 1, 2023
-26.59 KRW
Jan 1, 2024
-24.04 KRW
Jan 1, 2025
-16.09 KRW
The SCL Science ROE history
YEARROEYoY
-16.09 %-33.06%
-24.04 %-9.60%
-26.59 %-41.92%
-45.78 %-8.26%
-49.90 %+111.92%
-23.55 %-10.97%
-26.45 %-2.21%
-27.05 %-72.19%
-97.27 %+659.60%
-12.81 %-118.55%
69.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

ROE Details

Decoding SCL Science's Return on Equity (ROE)

SCL Science's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing SCL Science's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

SCL Science's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in SCL Science’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about SCL Science stock

Return on Equity (ROE) of SCL Science is -16.09 % in 2025.

Return on Equity (ROE) of SCL Science changed from -24.04 % to -16.09 %, representing a -33.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) SCL Science since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s SCL Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — SCL Science

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — SCL Science